Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Abbott fends off Chinese rival’s patent challenge at UPC
MedTech
The European court has backed Abbott in a dispute over glucose-monitoring technology, while offering guidance on a key added-matter issue.   18 August 2026
Former USPTO acting director takes the helm at C4IP
Careers
The IP advocacy group has turned to former USPTO acting director Coke Morgan Stewart as it enters what it calls a “new chapter”.   17 August 2026
Novartis scores UK win in high-stakes Entresto fight
Pharma
Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.   14 August 2026
MedTech
Clear aligner rivals are fighting over orthodontic technology across several major markets and the latest development in China has raised the stakes.   13 August 2026
Pharma
A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.   11 August 2026
Regulation & Industry
A federal judge has refused to disqualify Kirkland & Ellis from representing a healthcare tech company after a conflict check came under scrutiny.   7 August 2026
Pharma
A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.   6 August 2026
Careers
The 34-lawyer group prompts the launch of a Silicon Valley office and strengthens the firm’s technology, life sciences and global litigation capabilities.   6 August 2026
MedTech
The medical device maker says that a split appellate decision raises broader questions about trade secret law, jurisdiction and when the clock starts ticking on misappropriation claims.   3 August 2026
Pharma
A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.   31 July 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.